Colourful i-Base graphic. The main text reads: CROI 2026. Denver, Colorado. February 22nd to 25th. In the top left is i-Base’s website address: I hyphen base dot info. A smaller rectangle in the bottom right, reads: HIV news. 2026. In the top right and bottom left corners are signature CROI graphics, which are colourful illustrations of viruses. The colours used in the image are pale blue, pale green, orange, dark blue, purple, turquoise, yellow, white, pink, green, blue and black.

i-Base reports from #CROI2026. Main themes this year:

- ART pipeline
- #bNAbs in different settings
- #PrEP pipeline & #PEP
- Cure-related research
- GLP-1 agonists
- Political changes & impact of #HIVFundingCrisis

Our early summary – more to come later:
i-base.info/croi-2026-in...

#HIVsky #HIV

New vaccine platform promotes rare protective B cells Researchers developed a DNA-scaffolded vaccine that achieves the first step in generating a significant population of B cells that produce broadly neutralizing antibodies against HIV.

Forschung zur #HIV- Impfung: Sog. breit neutralisierende Antikörper #bNAbs könnten Baustein für neue HIV-Therapien und eine Impfung sein. Forscher*innen konnten nun mit DNA-basierten virusähnlichen Partikeln #VLPs die Produktion von B-Immunzellen anzuregen, die zur Bildung solcher bNAbs führen.

The #ENABLE kick-off meeting is underway in South Africa! @globalhealthedctp3.bsky.social

Penta will coordinate Ethics & Regulatory work for a trial testing 2 #bNAbs as intensification therapy alongside oral #ART in high-risk infants with #HIV 👶🏽

Excited to be part of this impactful project 🥰

Day 1 ✔️ #ENABLE project kicks-off today to prepare our clinical trial using #bNAbs to treat infants living with #HIV 👶🏽💙 Such a good start—strong ideas, great people, big goals 🚀 @globalhealthedctp3.bsky.social #EDCTP3

Frontiers | Harnessing mRNA for the expression of monoclonal IgG and IgA in non-human primates BackgroundMonoclonal antibodies (mAbs) are an increasingly essential class of medicines across many disease areas. In the human body, there are five antibody...

Harnessing mRNA for the expression of monoclonal IgG and IgA in non-human primates www.frontiersin.org/journals/imm... (open access) #HIV #bNAbs #mRNA

Enhanced Clearance of HIV-1 Broadly Neutralizing Antibody VRC07-523-LS During Viremia: Influences on Trial Design and Analysis ascpt.onlinelibrary.wiley.com/doi/10.1111/... (open access) #HIV #bNAbs

2️⃣Nach der faktischen Zerschlagung von USAID und dem Verlust der zugesagten Förderung haben die Forscher*innen einer geplanten #HIV- Impfstoffstudie mit breit neutralisierenden Antikörpern ( #bNAbs) mit viel Engagement eine neue Finanzierung gefunden, wenn auch nur ca. 5% der ursprünglichen Summe.

Ansicht der Front-Seite eines in Nature Medicine erschienenen Artikels zu den elf wichtigsten Studien im Bereich Medizin für 2026, unter denen sich auch eine Studie zu breit neutralisierenden Antikörpern in der Therapie von HIV befindet.

Nach Einschätzung von @nature.com Medicine gehören auch Studien zu den breit-neutralisierenden Antikörpern ( #bNAbs ) gegen #HIV zu den vielversprechendsten Studien in der Medizin im Jahr 2026.

Der Link zum Artikel ist hier:
www.nature.com/articles/s41...

Eleven clinical trials that will shape medicine in 2026 - Nature Medicine Nature Medicine asks leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID.

✨ Proud moment for the RIO team!
Our RIO clinical trial is featured in Nature Medicine, with our chief investigator Prof Sarah Fidler interviewed about the work. Huge thanks to our team and participants!

🔗 www.nature.com/articles/s41...
#HIVResearch #ClinicalTrials #ClinicalTrials #HIV #bNAbs

Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the Tatelo Study The Tatelo Study's long-term follow-up offers the first data on clinical, immunologic, and viral reservoir outcomes after combination bNAbs for pediatric t

Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the Tatelo Study academic.oup.com/cid/advance-... (subscription req for full text) #HIV #bNAbs #Tatelo @cidjournal.bsky.social

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies - Nature Communications A gene therapy method using AAV can help deliver HIV-fighting antibodies long-term, but the body often rejects them. Here the authors show that a short course of the drug rapamycin helps prevent host anti-drug antibody responses, showing successful antibody delivery in mice and monkeys.

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies www.nature.com/articles/s41... (open access) #HIV #AAV #bNAbs @natcomms.nature.com

The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig | AIDS Research and Human Retroviruses Adeno-associated virus (AAV)-vectored delivery of HIV-1 broadly neutralizing antibodies (bNAbs) holds promise for achieving durable HIV-1 immunity in a practical and scalable way, yet AAV-encoded bNAb...

The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig www.liebertpub.com/doi/10.1177/... (subscription req for full text) #HIV #bNAbs

🧬 6. Avances con anticuerpos (bNAbs)
🔬 Se prueban combinaciones para prevenir o controlar el virus
🧫 Aún no eliminan el VIH, pero son clave para futuras curas
#bNAbs #InvestigaciónVIH

🧵7/10

#bNAbs #InvestigaciónVIH

Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies Author summary There is an urgent need for alternative prevention and treatment strategies including vaccines and passively administered broadly neutralizing antibodies (bnAbs). Passive administration...

Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies journals.plos.org/plospathogen... (open access) #HIV #bNAbs

Published in #Immunity, a study led by @scripps.edu showed that a carefully designed two-step #vaccine regimen can induce the production of broadly neutralizing #antibodies #bNAbs that can block multiple strains of #HIV, including some of the most challenging #variants www.cell.com/immunity/abs...

A New HIV Vaccine Strategy: trigger a special type of antibody called broadly neutralizing antibodies (bNAbs) that capably target the lipid membrane surrounding the Human Immunodeficiency Virus. #HIV #vaccines #bNAbs #MPER #aids

Pair of IAVI publications demonstrate the potential value of bnAbs for HIV prevention Cost-effectiveness and acceptability in vulnerable populations assessed for HIV bnAbs. Learn more.

💡 New from IAVI: Two publications highlight the promising potential of broadly neutralizing antibodies (#bnAbs) in #HIV prevention.

🧬 Could bnAbs help shape the future of long-acting HIV prevention tools?

Find our more! 👇

Colourful i-Base image. The Rio Study Q&A. The heading in dark blue text on a light blue background reads: The RIO Study. Q and A is in large lettering, each a different bright colour on a coloured block. Main text, also in dark blue, reads: Read our Q&A for a breakdown of exciting results from this HIV cure-related study. White text on a small, tilted square graphic on the right, reads: HTB news. 2025. HIV treatment, prevention, access, and more. This block is made up of smaller blocks, coloured, dark blue, red, teal, orange and mustard. The logos for CROI and BHIVA are at the bottom of the image.

RIO study Q&A: i-base.info/htb/50971

- What is the #RIOstudy and how does it work?
- What are #bNAbs?
- What are the results and what do they mean?
- Has someone been cured of #HIV?

#CROI2025 #BHIVA25 #RIOtrial #HIVsky #ResearchSky #HIVcure #HIVresearch #HIVtreatment riotrial.bsky.social

@imperialctu.bsky.social RIO Team represented today at the @bhiva.bsky.social Spring Conference in Brighton 🤩 RIO Trial results presentation as part of the Oral Abstracts Session one - presented by RIO Chief Investigator, Prof Sarah Fidler 😊 #bhiva25 #riotrial #bnabs

Can Broadly Neutralizing Antibodies Keep HIV in Remission? Specialized HIV-fighting antibodies might one day be part of a strategy for a functional cure.

Broadly neutralizing antibodies (bnAbs) show promise in maintaining HIV remission post-ART, but their effectiveness varies. Ongoing research focuses on combination approaches to enhance outcomes. #HIVResearch #bnAbs
www.poz.com/article/can-...

Predictive markers for sustained viral suppression on dual... : JAIDS Journal of Acquired Immune Deficiency Syndromes n who were on ART since birth received up to 24 weeks of bNAb-only treatment (VRC01LS+10-1074). Suppression was defined as maintaining HIV RNA<400 copies/mL. HIV qualitative DNA and HIV RNA were perfo...

Predictive markers for sustained viral suppression on dual bNAbs during ART interruption in children journals.lww.com/jaids/abstra... (subscription req for full text) #HIV #ATI #bnabs

i-Base graphic. The main text in red and dark blue, on a light blue blue background, reads: CROI 2025. RIO study early results. Viral load remains undetectable off-ART, plus possible vaccine-like HIV cure. Below, in white on a burnt orange background, text reads, San Francisco, California. 9th to 12th March. On top of this is a faint image of the Golden Gate Bridge. In the top left corner is a URL: I hyphen base dot info. In the top right corner is a box made of blue, yellow and red blocks. White text on it reads, HTB news. 2025.

Exciting early riotrial.bsky.social‬ results at #CROI2025:i-base.info/htb/50530

New #bNABs so far successful in keeping viral load undetectable in some participants off #HIVtreatment.

Also the first time we’ve seen bNABs cause vaccine-like immune response.

#RIOtrial #teropavimab #zinlirvimab

The RIO Trial - using a new immune-based therapy to treat HIV This video is about a new HIV study called RIO. It uses a new immune-based therapy to treat HIV. The study is open to people who started HIV treatment soon after…

Hi everyone! We're very excited about joining the Bluesky community! This video explains our trial design and was coordinated by the Leadership group members: Simon Collins, Sarah Fidler, John Frater, Ming Lee and Hanna Box.
#hiv #riotrial #bNAbs #CROI

i-Base graphic. The main text in red and dark blue, on a light blue blue background, reads: CROI 2025. Conference on retroviruses and opportunistic infections. Below, in white on a burnt orange background, text reads, San Francisco, California. 9th to 12th March. Next to this is a faint image of the Golden Gate Bridge. In the top left corner is a URL: I hyphen base dot info. In the top right corner is the CROI logo, a colourful illustration of HIV.

i-Base reports from this year’s #CROI2025 conference:

i-base.info/htb/50463

Highlights from the programme include:
- New compounds and combinations for #HIVtreatment
- Access to #PrEP
- #bNAbs and cure-related research
- Weight changes and #GLP1 agonists

#islatravir #lenacapavir #LongActing

Prof Ole Søgaard opens today's #CROI2025 plenary on the progress of cure research.

#bNAbs are promising agents that act beyond ART as theg appear to enhance the frequency of viral control compared to previously reported rates of PTC.

Open access, previously available in a preprint version: www.biorxiv.org/content/10.1... #HIV #AAV #bNAbs

RIO HIV Trial - Viral suppression off ART using dual bNAb therapy RIO is looking at whether a new type of treatment, called bNAbs can keep viral load undetectable without antiretroviral treatment (ART)

My current research investigates the use of Broadly Neutralising Antibodies #bNAbs for HIV cure and remission strategies, particularly on their PK & impact on the HIV reservoir in tissue.

The RIO trial will the first powered db RCT of #bNAbs for PLWH. Read more about the #RIOtrial at riotrial.org

Broadly Neutralizing Antibodies: The “Emperor's New Clothes” of HIV Treatment? Laura Waters, M.D., FRCP shares her thoughts on the proliferation of recent research regarding broadly neutralizing antibodies in HIV, with a particular eye toward studies presented at CROI 2024.

Sogenannte breit neutralisierende Antikörper (engl. Abkürzung: #bNAbs) sind ein wichtiger Ansatz in der Forschung zur #HIV-Behandlung und #HIV-Heilung. Expertin Dr. Laura Waters ordnet die Forschung in einem (englischen) Video kritisch ein - auf der Seite ist auch ein Transkript zur Verfügung

bnAbs: From prevention to cure | IAS PlusUser menuTotal amount of likes

bnAbs: From prevention to cure, #IAS2023 Satellite, which I had the pleasure to contribute to. #HIV #bnAbs
plus.iasociety.org/webcasts/bna...